Search results for "Hydroxymethyl"

showing 10 items of 313 documents

Analysis of sterols by high-performance liquid chromatography/mass spectrometry combined with chemometrics

2006

A newly developed high-performance liquid chromatography/mass spectrometry (HPLC/MS) method has been successfully used to analyze plasma concentrations of various phytosterols (cholestanol and beta-sitosterol) and cholesterol metabolites (desmosterol and lathosterol). This was based on an unusual solvent combination of water/methanol vs. methanol/acetone/n-hexane applied on a Purospher Star RP-18e (125 x 2 mm, 3 microm) column, which proved excellent for the separation, identification and quantification of plasma sterols. Simple solid-phase extraction preparation of plasma samples was performed, followed by the developed fast and robust HPLC separation. Results on four groups of people were…

Settore MED/09 - Medicina InternaHypercholesterolemiaPilot ProjectsLathosterolMass spectrometryHigh-performance liquid chromatographyMass SpectrometryAnalytical ChemistryChemometricschemistry.chemical_compoundDesmosterolHumansHPLC/MS analysiChromatography High Pressure LiquidSpectroscopyChromatographyCholesterolCholestanolDesmosterolOrganic ChemistryExtraction (chemistry)cholesterol metaboliteDiscriminant AnalysisSitosterolsCholestanolSterolsCholesterolchemistrylipids (amino acids peptides and proteins)HPLCHydroxymethylglutaryl-CoA Reductase InhibitorsRapid Communications in Mass Spectrometry
researchProduct

Liver and Statins: A Critical Appraisal of the Evidence.

2019

Adverse drug reactions (ADRs) represent an important cause of morbidity and mortality worldwide. Statins are a class of drugs whose main adverse effects are drug-induced liver injury (DILI) and myopathy. Some of these may be predictable, due to their pharmacokinetic and pharmacodynamic properties, while others, unfortunately, are idiosyncratic. Genetic factors may also influence patient susceptibility to DILI and myopathy in the case of statins. This review will first discuss the role of statins in cardiovascular disease treatment and prevention and the underlying mechanisms of action. Furthermore, to explore the susceptibility of statin-induced adverse events such as myopathy and hepatoto…

Settore MED/09 - Medicina InternaOrganic Anion TransportersGenome-wide association studyBioinformaticsBiochemistryCytochrome P-450 Enzyme SystemHLA AntigensDrug DiscoveryMetSmedicineHumansGenetic Predisposition to DiseaseDrug reactionMyopathyAdverse effectDisease treatmentPharmacologybusiness.industryOrganic ChemistryStatinmedicine.diseaseHepatitis CHCV.Critical appraisalSingle Nucleotide Polymorphisms (SNPs)Cardiovascular DiseasesPharmacodynamicsliver damageMolecular MedicineATP-Binding Cassette TransportersMetabolic syndromemedicine.symptomChemical and Drug Induced Liver InjuryHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessgenetic susceptibilityCurrent medicinal chemistry
researchProduct

The clinical relevance of low-density-lipoproteins size modulation by statins.

2006

The predominance of small, dense low density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III; in fact, LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease. Several studies have also shown that the therapeutical modulation of LDL size is of great benefit in reducing the risk of cardiovascular events. Hypolipidemic treatment is able to alter LDL subclass distribution and statins are currently the most widely used lipid-lowering agents. Statins are potent inhibitors of hydroxy-methyl-glutaryl-coenzyme A reductase, the rate-limiting en…

Simvastatinmedicine.medical_specialtyIndolesStatinmedicine.drug_classAtorvastatinFatty Acids MonounsaturatedInternal medicineAtorvastatinmedicineHumansPyrrolesPharmacology (medical)RosuvastatinParticle SizeRosuvastatin CalciumFluvastatinNational Cholesterol Education ProgramPharmacologySulfonamidesVascular diseasebusiness.industryAnticholesteremic Agentsstatins small dense LDL coronary heart disease atherosclerosis prevention therapyGeneral Medicinemedicine.diseaseFluorobenzenesLipoproteins LDLPyrimidinesEndocrinologyCardiovascular DiseasesHeptanoic AcidsSimvastatinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessPravastatinmedicine.drugFluvastatin
researchProduct

CCDC 1565151: Experimental Crystal Structure Determination

2018

Related Article: Mirella Wawryszyn, Paul F. Sauter, Martin Nieger, Martin R.Koos, Christine Koehler, Burkhard Luy, Edward A. Lemke, Stefan Bräse|2018|Eur.J.Org.Chem.|2018|4296|doi:10.1002/ejoc.201800602

Space GroupCrystallography(2S3R4R5S6R)-3-(13-dioxoisoindolin-2-yl)-2-(ethylthio)-6-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)tetrahydro-2H-pyran-4-yl acetateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 863302: Experimental Crystal Structure Determination

2016

Related Article: Christine Wiebea, Silvia Fusté de la Sotilla, Till Opatz|2012|Synthesis|44|1385|doi:10.1055/s-0031-1290761

Space GroupCrystallography2-(23-dihydro-1H-indol-1-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-345-triol methanol solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2063842: Experimental Crystal Structure Determination

2021

Related Article: Ákos Bajtel, Mounir Raji, Matti Haukka, Ferenc Fülöp, Zsolt Szakonyi|2021|Beilstein J.Org.Chem.|17|983|doi:10.3762/bjoc.17.80

Space GroupCrystallographyCrystal System(3aS4R6R7aS)-3a-Hydroxymethyl-55-dimethylhexahydro-46-methanobenzo[d]oxazol-2(3H)-oneCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2080018: Experimental Crystal Structure Determination

2021

Related Article: V. Schmitt, G. Holzmann, D. Schollmeyer, H. Detert|2021|IUCrData|6|x210443|doi:10.1107/S2414314621004430

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters25-bis(hydroxymethyl)-NNN'N'-tetra-n-propyl-14-phenylenediamineExperimental 3D Coordinates
researchProduct

CCDC 1869183: Experimental Crystal Structure Determination

2019

Related Article: Shuai Liu, Yuping Zhao, Christian Heering, Christoph Janiak, Werner E. G. Müller, Sergi Hervé Akoné, Zhen Liu, Peter Proksch|2019|J.Nat.Prod.|82|1055 |doi:10.1021/acs.jnatprod.8b00938

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters2-(chloromethyl)-2-hydroxy-6-[2-(hydroxymethyl)-3-methoxy-3-oxoprop-1-en-1-yl]-5-(propan-2-yl)cyclohexane-1-carboxylic acid sesquihydrateExperimental 3D Coordinates
researchProduct

CCDC 1048445: Experimental Crystal Structure Determination

2015

Related Article: Í. Çelik, M. Akkurt, H. Akşit, R. Erenler, S. García-Granda|2015|Acta Crystallogr.,Sect.E:Cryst.Commun.|71|1425|doi:10.1107/S2056989015019623

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters34-Dihydroxy-3-(hydroxymethyl)-9-methyl-6-methyleneoctahydroazuleno[45-b]furan-28(3H4H)-dioneExperimental 3D Coordinates
researchProduct

CCDC 2123611: Experimental Crystal Structure Determination

2022

Related Article: Saurodeep Mandal, Arpan Dey Bhowmik, Alpana Mukhuty, Shampa Kundu, Khai-Nghi Truong, Kari Rissanen, Ansuman Chattopadhyay, Prithidipa Sahoo|2022|Scientific Reports|12|9307|doi:10.1038/s41598-022-13471-z

Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates1-[({[5-(hydroxymethyl)furan-2-yl]methylidene}hydrazinylidene)methyl]naphthalen-2-ol
researchProduct